Drug intelligence / Profile preview

anti-FL2 siRNA

Development stage: Preclinical
Lead developer: MicroCures
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Topical, Intradermal

Overview

anti-FL2 siRNA is a small interfering RNA (siRNA) drug developed by Albert Einstein College of Medicine and licensed to MicroCures. It targets and depletes Fidgetin-like 2 (FL2), a microtubule-severing enzyme that negatively regulates axon growth and cell motility. By inhibiting FL2, the drug aims to promote nerve regeneration. Preclinical studies in rats have shown its potential to regenerate erectile nerves damaged by prostate surgery, addressing neurogenic erectile dysfunction.

Targets

FL2 (Fidgetin-like protein 2)

Beyond the preview

Go deeper on anti-FL2 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-FL2 siRNA.

Explore the full profile